Skip to content

Rheumatoid arthritis — statistics sheet

Last curated: 2026-08-31. Figures are not pooled across incompatible definitions. Every row states source, year, population and method.

Population burden

Metric Figure Population/year Method Source
Global prevalent cases 17.6 million 204 countries/territories, 2020 GBD 2021 modelling GBD 2021 RA Collaborators 2023, PMID 37795020
Age-standardized prevalence 208.8 per 100,000 Global, 2020 GBD reference standard PMID 37795020
Projected prevalent cases 31.7 million Global, 2050 Demographic/GBD projection PMID 37795020
Absolute projected increase 14.1 million 2020→2050 Difference of reported counts PMID 37795020
Relative projected increase ~80% 2020→2050 31.7/17.6 − 1 PMID 37795020
Countries in earlier GBD series 195 1990–2017 GBD 2017 Safiri 2019, PMID 31511227
LMIC prevalent cases 12.6 million 129 low- and middle-income countries, 2023 GBD 2023 modelling Wang 2026, PMID 42495527
Upper-middle- versus low-income prevalence ratio 4.1-fold 129 LMICs, 2023 GBD 2023 modelling stratified by gross national income PMID 42495527

Classification and measurement thresholds

Metric Figure Population/year Method Source
2010 classification threshold ≥6/10 Eligible synovitis population ACR/EULAR criteria development Aletaha 2010, PMID 20872595
Joint-domain maximum 5 points >10 joints including ≥1 small joint Criteria score PMID 20872595
Serology maximum 3 points High-positive RF or ACPA Criteria score PMID 20872595
Duration contribution 1 point Symptoms ≥6 weeks Criteria score PMID 20872595
Validation cohort 270 Recent-onset arthritis, 2-year follow-up Prospective cohort Varache 2011, PMID 21572146
Boolean 2.0 tender joints ≤1 Trial validation datasets Remission definition Studenic 2023, PMID 36274193
Boolean 2.0 swollen joints ≤1 Trial validation datasets Remission definition PMID 36274193
Boolean 2.0 CRP ≤1 mg/dL Trial validation datasets Remission definition PMID 36274193
Boolean 2.0 patient global ≤2/10 Trial validation datasets Revised threshold PMID 36274193
SDAI remission ≤3.3 RA activity assessment Index threshold PMID 36274193
CDAI remission ≤2.8 RA activity assessment Index threshold Messelink 2023, PMID 37116986
DAS28 remission <2.6 RA activity assessment Historical index threshold Messelink 2023, PMID 37116986

Strategy and treatment-trial scale

Study/metric Figure Population/year Method Source
TICORA randomized 111 Active RA, 2004 Single-blind RCT Grigor 2004, PMID 15262104
TICORA screened 183 Two teaching hospitals Trial screening PMID 15262104
FIN-RACo randomized cohort 195 Early active RA Combination vs single DMARD RCT/follow-up Korpela 2004, PMID 15248204
ATTRACT randomized 428 Active despite MTX 54-week RCT Lipsky 2000, PMID 11096166
PREMIER randomized 799 Early aggressive MTX-naive RA 2-year RCT Breedveld 2006, PMID 16385520
TEMPO randomized 686 Active RA Double-blind RCT Klareskog 2004, PMID 15001324
AMBITION randomized 673 Active RA 24-week RCT Jones 2010, PMID 19297346
SELECT-COMPARE randomized 1,629 MTX inadequate response Phase 3 RCT Fleischmann 2019, PMID 31287230
R4RA randomized 164 Anti-TNF inadequate response Biopsy-stratified phase 4 RCT Humby 2021, PMID 33485455
Biologic poor response ~40% Established RA R4RA background estimate PMID 33485455
Failure after ≥4 advanced therapies 1.6% EULAR-defined D2T cohorts Meta-analysis Xie 2026, PMID 41188120

Safety and systemic burden

Metric Figure Population/year Method Source
ORAL Surveillance randomized 4,362 RA age ≥50 plus ≥1 CV risk factor Active-comparator safety RCT Ytterberg 2022, PMID 35081280
Tofacitinib doses tested 5 or 10 mg twice daily Same trial Randomized dose arms PMID 35081280
Mortality meta-analysis studies 17 RA cohorts Meta-analysis Lee 2024, PMID 38918258
Mortality meta-analysis patients 486,098 Multiple countries/eras Meta-analysis PMID 38918258
Deaths included 63,988 Same Meta-analysis PMID 38918258
RA-ILD share of RA mortality 10–20% Review-level estimate Literature synthesis Cassone 2020, PMID 32290218
RA-ILD mean survival cited in review 5–8 years Historical/heterogeneous RA-ILD cohorts Review synthesis PMID 32290218
RA-ILD JAK observational studies 7 Published through review search Systematic review Narváez 2024, PMID 39270812
RA-ILD incident-risk studies in same review 3 RA cohorts Systematic review PMID 39270812
RA-ILD prediction derivation cohort 1,156 Single center Retrospective model Yao 2025, PMID 41299487
Derivation RA-ILD cases 400 Same Retrospective model PMID 41299487
External validation cases/controls 178/178 Chinese registry External validation PMID 41299487

Difficult-to-treat, fatigue and precision

Metric Figure Population/year Method Source
Reported D2T prevalence range 5.5–27.5% Heterogeneous RA cohorts Review synthesis Hofman 2025, PMID 39383505
D2T poly-refractory cohort 1,591 b/tsDMARD-treated RA Cross-sectional ultrasound study David 2024, PMID 38059326
Blinatumomab compassionate series 6 Multidrug-resistant RA Case series Bucci 2024, PMID 38671240
Severe fatigue at least 1 in 6 Treated RA literature Review synthesis Pope 2020, PMID 32385141
Residual-symptom review reports 55 Literature through 2018 Systematic review Michaud 2021, PMID 32619340
Unique studies in residual review 53 Same Systematic review PMID 32619340
Plasma-proteome RA cohort 278 Longitudinal RA Proteomics cohort He 2025, PMID 40691443
At-risk participants in proteome study 60 Same Longitudinal cohort PMID 40691443
Healthy controls in proteome study 99 Same Cohort PMID 40691443
Baricitinib 24-month retention 58.2% overall; 42.0% D2T Japan; 353 total, 88 D2T 24-month observational cohort Ikeda 2026, PMID 42667647
Baricitinib CDAI remission 36.4% overall; 22.9% D2T Same Observational outcome PMID 42667647
TNFA methylation model AUC 0.760 combined versus 0.699 clinical-only 201 early untreated RA Treatment-response biomarker cohort Dalix 2026, PMID 42664067

Periodic-sweep additions — treatment and systemic outcomes

Metric Figure Population/year Method Source
Glucocorticoid use at 12 months 47% oral; 26% parenteral; 8% no early glucocorticoid 2,222 Canadian early-RA participants, 2007–2023 Observational cohort; exposure in first 3 months Fernández-Codina 2026, PMID 42665531
Adjusted odds of glucocorticoid use at 12 months OR 9.8 oral; 4.1 parenteral, versus no early glucocorticoid Same Multivariable logistic regression PMID 42665531
CKD-stage progression 106/601 over five years Japanese RA cohort Retrospective cohort Sugiyama 2026, PMID 42667508

Prevention trials

Metric Figure Population/year Method Source
ARIAA treatment duration 6 months ACPA-positive arthralgia + MRI inflammation Placebo-controlled RCT Rech 2024, PMID 38364841
ARIAA centers 14 Germany, Spain, Czech Republic Multicenter RCT PMID 38364841
APIPPRA UK centers 28 Autoantibody-positive inflammatory joint pain Phase 2b RCT Cope 2024, PMID 38364839
APIPPRA Netherlands centers 3 Same Phase 2b RCT PMID 38364839
TREAT EARLIER treatment duration 1 year Arthralgia + MRI subclinical inflammation Proof-of-concept RCT Krijbolder 2022, PMID 35871815
TREAT EARLIER follow-up 4 years ACPA-negative subgroup analysis Long-term follow-up Dumoulin 2024, PMID 39303731
TREAT EARLIER five-year overall RA onset 22% treatment vs 27% placebo; HR 0.79 (95% CI 0.47–1.34) 236 clinically suspect arthralgia participants Randomized follow-up Mulligen 2026, PMID 42392130
TREAT EARLIER increased-risk ACPA-negative subgroup 9% treatment vs 32% placebo; HR 0.24 (95% CI 0.07–0.87); NNT 4 66 participants; 5 years Prespecified risk-stratified follow-up PMID 42392130
APIPPRA/ALTO arthritis-free-survival difference 4.9 months (95% CI 0.1–9.6; p=0.044) at 4 years 143 long-term participants; median follow-up 55 months Masked randomized follow-up Cope 2026, PMID 41576971
StopRA clinical RA at 36 months 30.4% HCQ vs 32.9% placebo; risk difference −0.058 (95% CI −0.336 to 0.220) 142 modified-ITT anti-CCP3-high participants Phase 2 RCT Deane 2026, PMID 40884017

Known conflicts and caveats

  • GBD figures are modelled and should not be averaged with claims or examination-survey prevalence.
  • RA-ILD pooled prevalence is shown with I² and study design because systematic HRCT, clinical coding and symptomatic cohorts estimate different constructs; 18.7% is not a universal clinical prevalence.
  • Historical cervical-spine prevalence up to 80% comes from severe-era cohorts and is not a modern population estimate (Joaquim 2014, PMID 25151973).
  • D2T prevalence depends on whether symptoms, objective inflammation and access-related failure are included.
  • Trial enrollment is not an effect size; it is shown to indicate evidence scale.
  • Drug-class event rates cannot be transported across baseline cardiovascular, infection or cancer risk without absolute-risk recalculation.

Deepening additions — population and diagnostic performance

Metric Figure Population/year Method Source
Global pooled prevalence 0.46% (95% CI 0.39–0.54) 67 studies; 742,246 cases/211.6 million controls; literature 1980–2019 Random-effects meta-analysis; I²=99.9%, prediction interval 0.06–1.27% Almutairi 2021, PMID 33175207
Linked-data prevalence subgroup 0.69% (95% CI 0.47–0.95) Record-linkage studies Meta-analysis subgroup PMID 33175207
2010 criteria sensitivity/specificity 0.82 (95% CI 0.79–0.84) / 0.61 (0.59–0.64) 6,816 patients in 17 full articles Systematic review/meta-analysis Radner 2014, PMID 23592710
ACPA sensitivity/specificity 67% (95% CI 62–72) / 95% (94–97) 37 studies Diagnostic meta-analysis Nishimura 2007, PMID 17548411
ACPA positive/negative likelihood ratios 12.46 / 0.36 Same Diagnostic meta-analysis PMID 17548411
RF sensitivity/specificity 69% (95% CI 65–73) / 85% (82–88) 50 studies Diagnostic meta-analysis PMID 17548411
Major depression prevalence 16.8% (95% CI 10–24) 72 studies; 13,189 patients Diagnostic-definition meta-analysis Matcham 2013, PMID 24003249
PHQ-9-defined depression 38.8% (95% CI 34–43) RA cross-sectional studies Screening-instrument subgroup PMID 24003249

Deepening additions — treatment and strategy effects

Study/metric Figure Population/year Method Source
RACAT DAS28 change −2.1 triple therapy vs −2.3 etanercept–MTX; upper 95% confidence limit 0.41 below 0.6 margin 353 MTX inadequate responders; 48 weeks Double-blind noninferiority RCT O'Dell 2013, PMID 23755969
TEAR week-102 radiographic change 0.64 etanercept–MTX vs 1.69 triple therapy; p=0.047 Early aggressive RA; 2 years Randomized strategy trial Moreland 2012, PMID 22508468
CAMERA ever-remission 50% intensive vs 37% conventional; p=0.03 299 early RA; 2 years Open-label randomized strategy trial Verstappen 2007, PMID 17519278
BeSt one-year radiographic progression Median 2.0, 2.5, 1.0 and 0.5 across four strategies; p<0.001 508 early RA Randomized strategy trial Goekoop-Ruiterman 2005, PMID 16258899
NORD-STAR CDAI remission 39.2% conventional; 59.3% abatacept; 52.3% certolizumab; 51.9% tocilizumab 812 treatment-naive early RA; week 48 Randomized active-comparator trial Østergaard 2023, PMID 37423647
FINCH 2 ACR20 66.0% filgotinib 200 mg, 57.5% 100 mg, 31.1% placebo 448 biologic inadequate responders; week 12 Phase 3 placebo-controlled RCT Genovese 2019, PMID 31334793
ARCTIC primary endpoint 22% ultrasound target vs 19% clinical target; difference 3.3% (95% CI −7.1 to 13.7) 230 early RA; 2 years Randomized strategy trial Haavardsholm 2016, PMID 27530741
TaSER DAS44 change −2.69 ultrasound vs −2.58 clinical; between-group 95% CI −0.70 to 0.48 111 early RA; 18 months Randomized strategy trial Dale 2016, PMID 27026689

Deepening additions — systemic disease and safety

Metric Figure Population/year Method Source
MI incidence-rate ratio 2.10 (95% CI 1.52–2.89) 17 cohorts; 124,894 RA patients Meta-analysis Meune 2010, PMID 20656636
Stroke incidence-rate ratio 1.91 (95% CI 1.73–2.12) Same Meta-analysis PMID 20656636
RA-ILD pooled prevalence 18.7% (95% CI 15.8–21.6); I²=96.4% 56 studies; 11,851 RA-ILD cases Meta-analysis of heterogeneous definitions Wang 2024, PMID 38547537
RA-ILD UIP mortality HR 1.88 (95% CI 1.14–3.10) 23 eligible studies Prognostic meta-analysis Qiu 2021, PMID 34635095
INBUILD RA-ILD FVC decline −82.6 vs −199.3 mL/year; difference 116.7 (95% CI 7.4–226.1) 89 progressive RA-ILD participants; 52 weeks Randomized trial subgroup Matteson 2023, PMID 37209188
RA background VTE OR 2.23 overall; DVT 2.25; PE 2.15 272,884 RA/2.28 million controls Meta-analysis Hu 2021, PMID 34859863
Influenza satisfactory vaccine response 75.5% holding MTX 2 weeks vs 54.5% continuing; p<0.001 316 RA patients Randomized trial Park 2018, PMID 29572291
RA pregnancy preterm-delivery OR 1.83 11,999 RA pregnancies/9.92 million controls Meta-analysis Sim 2023, PMID 36544253
D2T pooled prevalence 11.7% (95% CI 9.5–14.3) 23 studies; 27,987 patients; 13 countries EULAR-definition meta-analysis Xie 2026, PMID 41188120
Persistently inflammatory share of D2T 47.1% (95% CI 33.3–61.4) D2T cohorts Meta-analysis PMID 41188120

Known conflicts and caveats — deepening addendum

  • Diagnostic sensitivity and specificity depend on the eligible population and reference standard; classification criteria, ACPA and RF rows are not screening performance in unselected pain.
  • The global 0.46% pooled prevalence has I²=99.9% and a 0.06–1.27% prediction interval; it must not replace a locally validated estimate.
  • Strategy-trial effects combine drug sequence, visit frequency, escalation rules and era; they are not pure drug effects.
  • RA-ILD estimates deliberately retain design and heterogeneity. HRCT-detected abnormalities, clinically coded ILD and progressive fibrotic RA-ILD are different denominators.
  • Relative safety estimates require baseline absolute risk, comparator, geography, dose and exposure time; “not statistically significant” does not establish equivalence.